Sasan Talaneh - Ph.D. Student of Medical Genetics, University of Medical Sciences, Tehran University, Tehran-Iran
Ali Sedghiani-Far - ral Practitioner - Urmia University of Medical Sciences- Urmia-Iran School of Medicine
Noshine Ansafi - Nursing expert, Urmia University of Medical Sciences, Urmia, Iran
masome abasi - General Practitioner - Urmia University of Medical Sciences- Urmia-Iran School of Medicine

Introduction & Aim:Breast cancer is the most common cancer among women, and one out of every eight women has breast cancer. Several genetic factors, such as HER2 genes, and estrogen and pergisterone receptors, play a significant role in the development of this disease. Micro-RNAs act as regulatory controls in the level of translation. If the racemic RNAs are not fully complementary to the RNA sequence, binding to them will result in the suppression of translation. The aim of this study was to determine the relationship between mir520 breast cancer breast cancer polymorphism in women. Materials and Method: Our survey population included 120 women with breast cancer approved by their respective physicians and divided into 3 groups. In the first group, women with estrogen and pergisterone receptor were assigned. In the second group, pregnant women received Herceptin 2 Epidermal Growth Factor (HER2) and the third group of women receiving 3 receptors. Real-time PCR and Berti analysis of data were analyzed using SPSS V24 software. Results: The relative level of gene expression in the first group was 0.199 and the second group was 0.92 and the third group was 0.42, which was observed only in the group with epidermal growth receptor (P = 0.03). Also, in both The group of women with stage 3 metastasis (P = 0.017) was 0.319 and women with metastatic lymph nodes (P = 0.42) had a significant decrease of 0.359. Conclusion: In women who had breast cancer with mutations in the MIR520 gene, the HER2 group showed a significant reduction in expression than other self-reported factors, indicating that MIR520 could be considered as one of the early detection factors in women You have HER2 to be used.

Breast Cancer - MIR520 - HER2 - Polymorphism